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Abstract
Introduction: Primary gallbladder neuroendocrine tumors are extremely rare, representing 0.2% of all
neuroendocrine tumors. The diagnosis is incidental in most cases.
Case presentation: We describe the case of a 57-year-old Caucasian man who underwent laparoscopic
cholecystectomy for the evaluation of a gallbladder polyp that had been incidentally detected by ultasonography.
Histologically, his lesion was composed of monomorphic cells that contained small round nuclei and that were
organized in small nodular, trabecular, and acinar structures. His cells were positive for chromogranin A and
synaptophysin, and a diagnosis of “typical” carcinoid of the gallbladder was made. His post-operative computerized
axial tomography,
111In-pentetreotide scintigraphy, and hormone-specific marker results were negative. He is
disease-free 45 months after surgical treatment.
Conclusions: Characteristic pathological findings of the gallbladder neuroendocrine tumors predict the prognosis.
Whereas classical carcinoids of the gallbladder only rarely have a metastatic or invasive phenotype, the “atypical”
variants are more aggressive and are associated with a poorer prognosis. Given the difficulty in distinguishing
between benign and malignant lesions in the pre-surgical setting, we tend to consider each polypoid-like lesion of
the gallbladder to be a high-risk lesion if it is larger than 1 cm and, as a result, to emphasize the need for
cholecystectomy in all cases, relying on the pathological and immunohistochemistry analyses for the final
diagnosis.
Introduction
Carcinoids are rare neuroendocrine tumors (NETs)
derived from enterochromaffin or Kulchitsky cells,
which are widely distributed in the body [1,2]. Conse-
quently, NETs can be found in any location of the body,
although the sites most commonly affected are the gas-
trointestinal and bronchopulmonary tracts, representing
approximately 67% and 25% of cases, respectively [3].
NETs are histologically varied entities and can range
from indolent, unrecognized neoplasms to highly active,
metastatic secretory tumors [4]. Prognostic factors
include primary tumor site, histological differentiation,
tumor size, angioinvasion, infiltrative growth, and pro-
duction of hormones [5]. Although the incidence of
NETs has increased over the past 30 years, survival has
also improved (reviewed by Zuetenhorst and Taal [2]).
According to American epidemiological data, gallblad-
der (GB) NETs are rare, representing only 0.2% of all
NETs [6]. Approximately half of the cases reported in
the literature as GB carcinoid tumors appear to be
endocrine cell carcinomas, which are histologically and
clinically distinct entities [6]. Whereas classical carci-
noids of the GB only rarely have a metastatic or invasive
phenotype, the “atypical” variants are more aggressive
and are associated with a poorer prognosis [6-9]. Here,
we describe a case of incidental GB carcinoid tumor in
a 57-year-old man.
Case presentation
A 57-year-old Caucasian man with a seven-year history
of hepatitis B virus infection was admitted to our hospi-
tal for the treatment of a GB polyp. The abdominal
ultrasonography (US) revealed the presence of a well-
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his GB fossa (Figure 1). No evidence of biliary dilatation
was noted, and there was no ascites. No image of stones
was documented (Figure 1).
On examination, there was no pertinent medical or
surgical history, and our patient was asymptomatic and
showed no evidence of jaundice. An abdominal exami-
nation revealed no tenderness or abnormal mass. The
results of laboratory assessments (complete blood count
and serum chemistry panel) on admission were normal.
On the basis of these data, a pre-operative diagnosis of
a single polypoid lesion of the GB (PLG) of larger than
1 cm was made and a laparoscopic cholecystectomy was
performed.
On gross inspection, the GB measured 6 cm and no
evidence of stones in our patient’sl u m e nw a sf o u n d .
However, a polypoid, yellowish lesion, measuring 11 × 8
mm, was found between the body and the neck of his
GB. Histologically, his tumor was composed of mono-
morphic cells containing small, round nuclei and eosi-
nophilic cytoplasm. His cells were organized in small
nodular, trabecular, or acinar structures surrounded by
a richly vascularized stroma but showed no mitotic
structures (Figure 2). Immunohistochemical studies
revealed that his cells were negative for cytokeratin,
vimentin, and CD-31 and CD-34 (Figure 3). His staining
r e s u l t sw e r ep o s i t i v ef o rt u m o rc e l lg r a n u l e so fs y n a p t o -
physin and chromogranin A (CgA) (Figure 4). Histologi-
cally, his GB lesion presented as an NET, and the final
diagnosis of “typical carcinoid” was made.
Post-operatively, our patient underwent a total body
computed tomography (CT) scan and bone scintigraphy
and the results were normal. The results of his
111In-
pentetreotide scintigraphy, which is used to detect cells
with somatostatin receptors, were also normal. His
blood levels of glucagon, serotonin, vasoactive intestinal
peptide, somatostatin, and gastrin were normal, as were
Figure 1 Abdominal ultrasound image of a polypoid mass
between the neck and body of a gallbladder.
Figure 2 Hematoxylin-and-eosin section of a carcinoid tumor.
An organ-like growth pattern and rosettes with large cells,
prominent nucleoli, and coarse “salt and pepper” chromatin are
shown. Magnifications: ×2.5 (A), ×10 (B).
Figure 3 Tumor cells did not express cytokeratin (A), vimentin
(B), CD-31 (C), or CD-34 (D), as revealed by
immunohistochemistry. Endothelial cells positive for CD-31 (C) and
CD-34 (D). Magnification: ×20.
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(5-HIAA) and CgA. After an uneventful recovery, our
patient was discharged in good condition, and he is dis-
ease-free 45 months after surgical treatment.
Discussion
Primary GB carcinoids are extremely rare. The first
case of a carcinoid tumor of the GB was reported in
1929, and 43 cases of carcinoid tumors have been
reported to date. Approximately half of the reported
cases of GB carcinoid tumors appear to be endocrine
cell carcinomas [3-10]. At present, 278 cases of GB
NETs are reported in the Surveillance, Epidemiology,
and End Results (SEER) database. Only five well-differ-
entiated NETs are registered in SEER, indicating that
the entity of “benign” NETs is very rare in the GB [1].
Neuroendocrine cells derive from local multipotent
gastrointestinal stem cells rather than, as initially
guessed, by migration by the neural crest. GB NETs
may develop from endocrine cells induced by intestinal
metaplasia of the body and fundus as well as from pre-
existing endocrine cells in the neck of the GB [1-11].
The age at presentation of GB NETs ranges from 38 to
81 years, and there is a markedly higher incidence in
w o m e n[ 1 0 ] .C a r c i n o i ds y n d r o m ei sv e r yr a r e( < 1 % ) ,
and most GB carcinoids are diagnosed incidentally
during a histological examination of GB specimens at
autopsy, after cholecystectomy for acute or chronic
cholecystitis, or after surgery for another suspected
biliary pathology [6-8,12-17].
The case reported here was initially diagnosed as a
polyp after an ultrasound examination. PLGs are readily
detected by US [18] with high specificity (95.8%) [19].
The lifetime prevalence of GB polyps ranges from 1% to
4%. PLGs are “incidentally detected” in approximately 4%
to 7% of patients undergoing US of the GB [20], and PLG
is one of the most common diseases in biliary surgery.
The majority of GB polyps are non-neoplastic and
most commonly include cholesterol polyps (60%) or
inflammatory ones (10%). Adenomyomas represent the
second most common type of GB polyps (25%). This
type of lesion is associated with an increased incidence
of GB cancer, and the GB should be removed surgically.
Adenonomatous polyps represent a minority. They can
progress to cancer, and this risk is related to their size:
polyps larger than 1 cm are considered high-risk lesions.
The fifth class of GB polyps consists of rare lesions that
include heterotopic gastric glands, neurofibromas, carci-
noid tumors, leiomyomas, and fibromas.
The specificity of abdominal US in PLG detection is
high [19], but the sensitivity of US was reported to be
l o w[ 2 1 ] .E n d o s c o p i cU S( E U S )m a yb e c o m et h es t a n -
dard to define PLGs. Studies have shown a correlation
between EUS characteristics and the actual histology of
PLGs. EUS is considered to be superior to all types of
imaging for GB lesions, particularly for early GB cancer
because of the higher operating frequency (7.5 to 12
MHz) that can provide high-resolution images of small
lesions and a diagnostic sensitivity for GB malignancy of
90% [21]. High-resolution US (HRUS) has demonstrated
a diagnostic sensitivity of as high as 90% and an accu-
racy of 62.9% for staging the depth of cancer invasion
[22]. Both EUS and HRUS minimize the changes of not
identifying pre-malignant lesion. If the polyps are severe
or appear malignant or if large or irregular lesions are
found, a CT scan should be performed in order to avoid
missing a GB carcinoma. Pre-operative suspicion and a
differential diagnosis of GB cancer are very important
for selecting the optimal treatment. CT could be used
not only to distinguish an early GB carcinoma from a
PLG but also to assess the tissue around the malignant
PLG and regional lymph node metastases [19]. Although
imaging such as US, EUS, or CT has been widely used,
it is still difficult to differentiate cancer from non-neo-
plastic lesions before an operation. Hence, differentiating
a pre-cancerous lesion from early GB cancer is essential.
The risk of malignancy is between 45% and 67% in
polyps from 1 to 1.5 cm in size [21].
Operative indications for PLGs included a maximal
diameter of 1 cm, a wide-base lesion, lesions tending to
become enlarged in a short period, patient age of more
than 50 years, a single polypoid lesion, coexisting GB
stones, and a PLG associated with irregular thickening
of the local GB wall.
Figure 4 Tumor cells stained positive for chromogranin A (A,
B) and for synaptophysin (C, D). Magnifications: ×2.5 (A, C), ×10
(B, D).
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were suggestive of an NET tumor. The determination of
the histological type of the tumor and differential diag-
nosis from GB adenocarcinoma are often difficult. The
identification of neuroendocrine cells and the immuno-
histochemical expression of marker proteins as well as
other cell type-specific amines and peptides are neces-
sary to define a GB NET. Our patient’s immunohisto-
chemistry test results were negative for cytokeratin,
vimentin, and CD-31 and CD-34, allowing us to exclude
a likely diagnosis of adenocarcinoma, sarcoma, or vascu-
lar tumor, respectively. The combination of the high his-
tological differentiation, the tumor size, the absence of
angioinvasion and infiltrative growth, and the immuno-
histochemical staining supported the final diagnosis of a
“typical” rather than of an “atypical” NET tumor.
When feasible, surgical treatment, with the goal of
complete resection, is the gold standard for typical car-
cinoids of the GB. For pre-invasive and early-detected
cancer (T1s and T1), simple cholecystectomy is probably
an adequate therapy. For advanced lesions, a more
aggressive radical surgery, including radical cholecystect-
omy and regional lymphadenectomy combined with a
hepatic resection in order to obtain adequate free mar-
gins, is needed [1]. Additional therapies in an adjuvant
setting are not required for typical carcinoids according
to the low metastatic potential of the neoplasia as well
as to the general insensitivity to traditional radiotherapy
and chemotherapy in low-grade cancer disease.
For many years, sieric CgA and urinary 5-HIAA, each
of which has a specificity of nearly 100% but a low sen-
sitivity, have been the gold standard for detecting carci-
noids and conducting follow-up [23].
111In-pentetreotide
has a high affinity for somatostatin subtype 2 and 5
receptors, which are present on the cell membranes of
carcinoid tumor cells, making
111In-pentetreotide scinti-
graphy a good technique for imaging carcinoid tumors
[24]. Standard bone scintigraphy has a higher sensitivity
for the detection of bone metastases in patients with
carcinoid tumors [25]. Post-operative specific tumor
markers, total body CT,
111In-pentetreotide scintigraphy,
and bone scintigraphy tests in our patient were all nor-
mal, indicating the lack of metastases and the successful
surgical treatment of a “typical” carcinoid of the GB.
Indeed, in one study, 82.4% of GB carcinoids remained
localized and only 11.8% of patients demonstrated dis-
tant metastases [3]. The same source reported a five-
year survival of 60.8% ± 14.8%. Modlin and colleagues
[1] reported a median survival of 9.8 months among 278
cases of GB NETs reported in SEER. The five-year sur-
vival rates for tumors classified as carcinoids-neuroen-
docrine carcinoma or small-cell cancer were 36.9% and
0%, respectively [1].
Conclusions
Considering the difficulties in making a pre-operative
differential diagnosis between a benign “typical” carci-
noid and the more aggressive “atypical” variants or
between NET, adenocarcinoma, and benign lesions of
the GB, we emphasize the need for surgical manage-
ment for any suspected polypoid lesion, relying on the
pathologist and immunohistochemistry analyses for the
final diagnosis. We underline the need to distinguish
between different forms of NETs of the GB with differ-
ent metastatic potential, prognosis, and clinical course.
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